Knight Therapeutics Inc. has seen a modest uptick in its stock price this week, driven by a series of positive financial announcements.
Knight Therapeutics Inc. (GUD.TO) reported a slight increase of 0.41% over the past week, closing at C$9.97. The company has recently garnered attention for its strong quarterly results and updated financial guidance, reflecting a positive trajectory in its business operations.
Advertisement
Knight Therapeutics Inc.
GUD.TO
GUD.TO
Knight Therapeutics Inc.
WealthAwesomeMarket cap
$957.76M
P/E
65.0x
52W high
$10.17
52W low
$5.66
1W change
-0.61%
Beta
0.05
Analyst Price Targets
Based on analyst covering GUD
Wall Street analysts forecast GUD stock price to rise 14.6% over the next 12 months.
Consensus
Moderately BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$11.19
+14.6% Upside
Current Price
C$9.76
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GUD's historical volatility
30-Day Vol
32.3%
Annualized
90-Day Vol
32.3%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$11.67
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$10.36 | C$9.27 โ C$11.58 |
| 60 trading days | C$10.99 | C$9.39 โ C$12.87 |
| 90 trading days | C$11.67 | C$9.62 โ C$14.15 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors might find Knight Therapeutics' recent performance encouraging, especially with its improved revenue guidance and repayment of debt, although the high P/E ratio suggests caution.
Knight Therapeutics Reports Record Revenues and Increased Guidance
The company has raised its 2026 revenue guidance from $510 million to $525 million, signaling confidence in its growth trajectory.
Bull case
Knight Therapeutics has reported record-high revenues and adjusted EBITDA, suggesting strong operational performance and promising growth potential.
Bear case
However, with a P/E ratio over 163, some may view the stock as overvalued. Any market corrections could lead to significant volatility, especially given its low beta of 0.05.
Recent Performance
Knight Therapeutics Inc. (GUD.TO) has shown steady performance over the last week, with a modest gain of 0.41%. The stock closed at C$9.97, reflecting a year-to-date increase of 66.50%. This positive trend can be attributed to the company's recent financial announcements and operational successes.
Catalysts Behind the Movement
Advertisement
The recent uptick in Knight Therapeutics' stock is largely due to the company's announcement of record-high quarterly revenues and adjusted EBITDA for Q1 2026. Additionally, the company has raised its revenue guidance for 2026 from $510 million to $525 million, indicating strong growth prospects. Furthermore, the successful repayment of its revolving credit facility has strengthened its financial position.
Technical Picture
Looking at the technical indicators, Knight Therapeutics is trading above its 50-day moving average of C$9.07, representing a 9.9% premium. The stock is also significantly above its 200-day moving average of C$7.01, showing a 42.3% increase. The 52-week range is C$5.66 to C$10.17, indicating that the stock is currently trading at about 96% of its 52-week high. With a beta of 0.05, the stock exhibits low volatility compared to the market.
Insider Activity
As of now, there are no reported insider activities that could influence investor sentiment or stock performance.
Price Action Summary
Knight Therapeutics Inc. closed at C$9.97, reflecting a 1D increase of 0.20%. The stock continues to attract attention as it navigates a positive financial landscape.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
